Drug Profile
Efocipegtrutide - Hanmi Pharmaceutical
Alternative Names: GLP-1/GIP/glucagon triagonist - Hanmi Pharmaceutical; HM-15211; LAPS-triple agonistLatest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antidementias; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Antiparkinsonians; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Phase I Non-alcoholic fatty liver disease
- Preclinical Hepatic fibrosis; Idiopathic pulmonary fibrosis
- Discontinued Alzheimer's disease; Dyslipidaemias; Multiple sclerosis; Obesity; Parkinson's disease; Type 2 diabetes mellitus
Most Recent Events
- 10 Nov 2023 Pharmacodynamics data from a preclinical trial in Liver Injury presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 21 Jun 2023 Pharmacodynamics data from a preclinical studies in Hepatic fibrosis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
- 21 Jun 2023 Pharmacodynamics data from a preclinical studies in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)